Denmark could eradicate cervical cancer by 2040: Study
14 Apr 2025 14:14
Copenhagen (AFP)Denmark aims to eradicate cervical cancer by 2040 thanks to a national HPV vaccination campaign and screening programme, the Danish Cancer Society said on Monday."Even before 2040, so few women may have the disease that it may be considered eradicated," the Danish Cancer Society said in a statement."It would be the first time a cancer has disappeared," it said.The current cervical cancer rate in Denmark is lower than 10 out of 100,000 women, according to a study in the Danish medical journal Ugeskrift for Laeger.According to the World Health Organization's (WHO) criteria, the disease would be considered eradicated when there is an incidence rate lower than four per 100,000 women.In Denmark, the vaccination rate against human papillomavirus (HPV), the main cause of the disease, is 89% for girls and boys aged 12, for the first of two doses. That's just shy of the 90% goal.The free vaccine was introduced for girls in 2008-2009 and for boys in 2019.In addition, 60% of women in Denmark accept the offer of free screenings, slightly lower than the 70% participation target.
Neighbouring Sweden could however beat Denmark to the post: it aims to eradicate cervical cancer by 2027, according to the Regional Cancer Centres in Sweden.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
a day ago
- Al Etihad
WHO maintains mpox public health alert amid West Africa surge
9 June 2025 23:59 GENEVA (AFP)The World Health Organisation said Monday that the mpox virus epidemic remains an international health emergency, with more than 37,000 confirmed cases reported since it director general Tedros Adhanom Ghebreyesus announced the extension of the emergency, following a meeting of international experts who noted progress in some countries but also highlighted a surge in west Africa and the spread of the virus outside WHO said since the epidemic started in early 2024 in Democratic Republic of Congo, there have been more than 37,000 cases in 25 countries, including 125 Congo accounts for 60 percent of the confirmed cases and 40 percent of the deaths from the virus, which causes a rash and severe flu-like and Burundi have been the next worst hit, followed by Sierra Leone, which the WHO said has seen a surge in cases this first declared mpox an international emergency in August last year. The International Health Regulations emergency committee met last Thursday to discuss the decided that the epidemic remains an international emergency "based on the continuing rise in the number of cases, including a recent increase in West Africa, and likely ongoing undetected transmission in some countries beyond the African continent." WHO also said some countries were still struggling to monitor the epidemic and with a lack of funding for treatment there was a need for "continued international support".
Middle East Eye
2 days ago
- Middle East Eye
Israeli strike kills two near aid distribution centre in southern Gaza
An Israeli air strike on civilians near the aid distribution point in the west of Rafah, in southern Gaza, killed at least two people, according to health officials at the Nasser Medical Complex. Civil defence spokesman Mahmud Bassal and witnesses said the civilians had been heading to a site run by the US-backed Gaza Humanitarian Foundation. Witness Abdallah Nour al-Din told AFP that "people started gathering in the Al-Alam area of Rafah" in the early morning. "After about an hour and a half, hundreds moved toward the site and the army opened fire," he said. At a charity kitchen in Gaza City, displaced Palestinian Umm Ghassan said she had been unable to collect aid from a GHF site "because there were so many people, and there was a lot of shooting." "I was afraid to go in, but there were people who risked their lives for their children and families," she said.
Gulf Today
3 days ago
- Gulf Today
Man's extreme snake bite trials boost new antivenom research hope
Tim Friede was feeling particularly down on the day after the Sept.11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him. Four days later, he woke up from a coma. "I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin. This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time. From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times. Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home. Tim Friede can be seen with a snake in this undated image. Instagrm photo After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists. But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom. The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom. This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes. Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organisation (WHO). These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas. 'Pain every time' Friede's first bite was from a harmless garter snake when he was five years old. "I was afraid, I cried, I ran away," said Friede, now 57. Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted. Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom. How antivenom is made has changed little over the last 125 years. Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom. However this antivenom usually only works for bites from that particular species of snake — and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock. "I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said. He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes. "There is pain every time," he said. Antibodies For years, the scientists he contacted to take advantage of his immunity refused to bite. Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom. Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites. When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood." "I've been waiting for this call for a long time," came the response, Glanville said. The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib. It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six. The researchers hope a future cocktail will cover far more snakes — particularly vipers — with further trials planned on dogs in Australia. Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies. 'Proud' Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down. Friede said he was "proud" to have made a "small difference" in medical history. Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues. But he hopes to get bitten by snakes again in the future. "I do miss it," he said. Agence France-Presse
